Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Oyster Point Pharma Inc (NQ: OYST ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Dec 30, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 11.06 (41) Ask (Size) 11.17 (20) Prev. Close 11.17 Today's Range N/A - N/A 52wk Range N/A - N/A Shares Outstanding 26,014,621 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7 February 21, 2024 Goldman Sachs' Hedge Fund Trend Monitor highlights concentration in mega-caps, with optimism in AI and health care. Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence The 7 Best Crypto and Stocks to Buy as Christmas Gifts This Year December 21, 2022 These stocks to buy as Christmas gifts provide a number of reasons for investors to rejoice this holiday season. Via InvestorPlace Performance More News Read More The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond December 18, 2022 Via InvestorPlace OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST December 07, 2022 From Kahn Swick & Foti, LLC Via Business Wire Why Viatris Stock Is Jumping Today November 07, 2022 Via The Motley Fool Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 02, 2022 From Oyster Point Pharma, Inc. Via GlobeNewswire Better Dividend Stock: AbbVie or Viatris? November 26, 2022 Via The Motley Fool Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights November 10, 2022 From Oyster Point Pharma, Inc. Via GlobeNewswire OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST November 08, 2022 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO) November 08, 2022 From Brodsky & Smith LLC Via GlobeNewswire Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25% November 08, 2022 Via Benzinga Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday November 08, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022 November 08, 2022 Via Benzinga Dow Surges 400 Points; Crude Oil Down 1% November 07, 2022 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session November 07, 2022 Via Benzinga Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday November 08, 2022 Via Benzinga Analyzing Oyster Point Pharma's Short Interest November 07, 2022 Via Benzinga Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session November 07, 2022 Via Benzinga Dow Jumps Over 200 Points; Verve Therapeutics Shares Plummet November 07, 2022 Via Benzinga Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share November 07, 2022 Via Spotlight Growth Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge November 07, 2022 Via Benzinga Viatris (VTRS) Stock Pops 17% on Acquisition News November 07, 2022 Via InvestorPlace US Stocks Mixed; Dow Rises Over 50 Points November 07, 2022 Via Benzinga OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders November 07, 2022 From Halper Sadeh LLC Via Business Wire Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris November 07, 2022 From Oyster Point Pharma, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.